Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1CNS 1

Conditions

Neoplasm Metastasis 7Carcinoma, Non-Small-Cell Lung 6Triple Negative Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Skin Neoplasms 3Melanoma 3Head and Neck Neoplasms 3Breast Neoplasms 3Recurrence 2Prostatic Neoplasms 2Ovarian Neoplasms 2Neoplasms 2Mycosis Fungoides 2Multiple Myeloma 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Follicular 2Lymphoma, B-Cell 2Glioblastoma 2Colorectal Neoplasms 2Advanced Malignancies 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Stomach Neoplasms 1Recurrent Squamous Cell Carcinoma of Head 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Myelodysplastic Syndromes 1

Interventions

Temozolomide 41Radiotherapy 15Magnetic Resonance Spectroscopy 12Surgical Procedures, Operative 10Bevacizumab 10Irinotecan 9Radiation 8Nivolumab 7Carmustine 7Specimen Handling 6Radiosurgery 6Carboplatin 6ribociclib 5O(6)-benzylguanine 5Imiquimod 5IL13-PE38 5Flucytosine 5Filgrastim 5Erlotinib Hydrochloride 5Cyclophosphamide 5Aminolevulinic Acid 5vandetanib 4sargramostim 4Topotecan 4Lomustine 4Imatinib Mesylate 4Etoposide 4Craniotomy 4vocimagene amiretrorepvec 3temsirolimus 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Glioma × cemiplimab × Clear all
NCT04826393 2025-10-22

ASP8374 + Cemiplimab in Recurrent Glioma

Dana-Farber Cancer Institute

Phase 1 Completed
14 enrolled
CNSLymphoid

Glioblastoma, Glioma, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡